Document:

Unassociated Document

 

ASSET PURCHASE AND STOCK TRANSFER AGREEMENT

 

THIS ASSET PURCHASE AND STOCK TRANSFER AGREEMENT (hereinafter referred to as the "Agreement") is made and entered into as of the  15th   day  of January
2004 (the "Effective Date"), by and between:

 

OXYSURE SYSTEMS, INC., a company duly organized and existing pursuant to the laws of the State of Delaware, (hereinafter referred to as "OSI" or the "Company");

 

ROSS GLOBAL, INC., a company duly organized and existing pursuant to the laws of the State of Nevada, (hereinafter referred to as "RGI");

 

JTR INVESTMENTS LIMITED, a Texas Limited Partnership (hereinafter referred to as "JTRIL"); and

 

JULIAN T. ROSS, a key employee of RGI (hereinafter referred to as "Ross").

 

 

WITNESSETH:

 

WHEREAS, The Company was formed to carry on business as a medical devices organization with special emphasis on marketing portable respiratory equipment and devices;

 

WHEREAS, RGI and Ross have jointly developed a unique method and apparatus for generating medically pure oxygen utilizing a catalytic process, and which catalytic process utilizes two chemical powders consisting of a reagent and a proprietary catalyst;

 

WHEREAS; OSI desires to acquire certain assets, including certain rights, title and interest to the collective intellectual property, relating to the oxygen method and apparatus, developed by RGI and Ross, and whereas OSI desires to acquire this collective intellectual property;

 

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements hereinafter set forth, the parties hereto mutually covenant and agree as follows:

 

	1. 	
DEFINITIONS. Whenever used in this Agreement, the following terms shall have the meanings set forth below:

 

	 	(a)	"Affiliate" shall mean any corporation or other entity that is directly or indirectly controlling, controlled by or under tire common control with a party hereto for so long as such control exists. For the purpose of this Agreement, "control" shall mean the direct or indirect ownership of fifty percent (50%) or more of the outstanding shares or other voting rights of the subject entity to elect directors, or if not meeting the preceding,
any entity owned or controlled by or owning or controlling at the maximum control or ownership right permitted in the country where such entity exists.

 

 

 

1

 

 

	 	(b)	
"Licensee" means a third party to whom OSI has granted a license or sublicense under the Patents, to make, have made, import, use, sell, offer for  sale or otherwise exploit a Product. "Licensee" includes a third
party to whom OSI has granted the right to distribute a Product.

 

	 	(c)	
"Patents" shall mean (i) that certain patent entitled "Method and Apparatus for Generating Oxygen" filed with the United States Trademark and Patent Office on November 20, 2003, marked Exhibit A, which patent is assigned by Ross to OSI pursuant to that certain Assignment Agreement dated January 15, 2004 (the "Assignment Agreement"); and (ii) all related patents applied
for or filed by Ross, or to be filed by or applied for by Ross subsequent to the Effective Date, and which patents shall be assigned by Ross to OSI pursuant to that certain Employment Agreement between OSI and Ross dated January 15, 2004 (the "Employment Agreement").

 

	 	(d)	
"RGI Technology" means technological models, algorithms, manufacturing processes, design drawings (whether manual or electronic), design processes, prototypes, behavioral models, schematics, test vectors, know-how, computer and electronic data processing and other apparatus programs and software, databases and documentation thereof, trade secrets, technical information,
specifications, drawings, records, documentation, works of authorship or other creative works, ideas, knowledge, data or the like that is owned by or licensed to RGI (to the extent RGI may grant a license or sublicense to such intellectual property) as of the Effective Date, including without limitation information useful to the practice of the inventions claimed in the OSI Patents, except that RGI Technology shall exclude any and all information, know-how, formulation or trade secrets relating to the manufacture
of the "Catalyst", whether developed prior to or subsequent to the Effective Date.

 

	 	(e) 	
"Product" shall mean any equipment, products, processes or methods covered by or that exploit or make use of one or more Valid Claims or that exploit or make use of the RGI Technology, including, without limitation, any and all respiratory or medical devices, portable or otherwise, including emergency-duration oxygen dispensers and related accessories, sold under or utilizing
tire "Oxysure Logo Trademark", or the "Oxysure Name Trademark", or the "Oxysure Tag Line Trademark".

 

	 	(f) 	
"Catalytic Reaction" shall mean that certain chemical reaction, covered by a Valid Claim, between two powders that produces medically pure oxygen and which chemical reaction is utilized in the Product, where applicable, to generate medically pure oxygen.

 

 

 

 

2

 

 

 

	 	(g)	
"Valid Claim" means a claim of any Patent that has not expired, lapsed, or been held invalid, unpatentable or unenforceable.

 

	 	(h)	
"Reagent" shall mean that certain powder used in the Catalytic Reaction to generate the oxygen.

 

	 	(i)	
"Catalyst" shall mean that certain catalyst used to initiate or otherwise accelerate the Catalytic Reaction.

 

	 	(j)	
"Oxysure Logo Trademark" shall mean that certain trademark owned by RGI and filed with the United States Patent & Trademark Office, consisting of the word "Oxysure" in green with a stylized letter O, marked "Exhibit B".

 

	 	(k) 	
"Oxysure Name Trademark" shall mean mat certain trademark owned by RGI and filed with the United States Patent & Trademark Office, consisting of the word "Oxysure" in standard character format without claim to any particular font style, size or color, marked "Exhibit C".

 

	 	(1)	
"Oxysure Tag Line Trademark" shall mean that certain trademark owned by RGI and filed with the United States Patent & Trademark Office, consisting of the words "Pure Oxygen from Powder" in standard character format without claim to any particular font style, size or color, marked "Exhibit D".

 

	 	(m) 	
"Domain  Name"  shall  mean  the  Universal  Record  Locator (URL) http://www.oxysure.com or www.oxysure.com or oxysure.com.

 

	 	(n) 	"Securities Act" shall mean the Securities Act of 1933, as amended.

 

2.      ASSET PURCHASE.

 

	
2.1  
	
RGI Technology. Subject to tire provisions set forth herein, RGI hereby transfers to OSI all rights, title and interest to the RGI Technology; OSI shall have tire right to grant an exclusive, worldwide, perpetual, irrevocable license to another party, or grant exclusive or non-exclusive sublicenses, to commercialize, use, reproduce, translate, distribute
(by any means known or hereafter developed, including electronic distribution), market, make derivative works of and otherwise exploit the RGI Technology.

 

	
2.2  
	
Patents. Subject to the provisions set forth herein, RGI and Ross hereby transfers to OSI all rights, title and interest the Patents. OSI shall have the right to grant an exclusive, worldwide, perpetual, irrevocable license to another party, or to grant exclusive or non-exclusive sublicenses, under the Patents, to commercialize, make, sell, offer for sale,
import and use products, and to perform processes, products and methods, that embody the inventions described in the Patents. Ross shall assign the Patents to OSI, pursuant to that certain Assignment Agreement dated March 24, 2004 and that certain Employment Agreement made between OSI and Ross dated January 15, 2004.

 

 

3

 

 

 

	
2.3  
	
Trademarks. Subject to the provisions set forth herein, RGI hereby transfers to OSI all rights, title and interest to the Oxysure Logo Trademark, Oxysure Name Trademark, and the Oxysure Tag Line Trademark. OSI shall have the right to grant an exclusive, worldwide, perpetual, irrevocable license to another party, or to grant exclusive or non-exclusive sublicenses,
to reproduce, copy, market with, make derivative works of, use in commerce, or otherwise exploit the Oxysure Logo Trademark, Oxysure Name Trademark, and the Oxysure Tag Line Trademark. Ross shall assign the Oxysure Logo Trademark, Oxysure Name Trademark, and the Oxysure Tag Line Trademark to OSI.

 

	
2.4  
	
Domain Name. Subject to the provisions set forth herein, RGI hereby transfers to OSI all rights, title and interest the Domain Name. OSI shall have the right to grant an exclusive, worldwide, perpetual, irrevocable license to another party, or to grant exclusive or non-exclusive sublicenses, to host websites, publish and distribute information via the
World Wide Web, host and operate email, generally use in commerce, or otherwise exploit the Domain Name.

 

	
2.5  
	
Product. Subject to the provisions set forth herein, RGI hereby transfers to OSI all rights, title and interest the Product. OSI shall have the right to grant an exclusive, worldwide, perpetual, irrevocable license to another party, or to grant exclusive or non-exclusive sublicenses, to commercialize, make, package, repackage, sell, offer for sale, market,
import or distribute the Product.

3.           CONSIDERATION

 

	
3.1  
	
Stock Issuance. OSI shall issue to RGI six million (6,000,000) shares of common stock at par. In addition, OSI shall issue to JTRIL sixty-four million (64,000,000) shares of its common stock at par. Stock issued in terms hereof shall have anti­dilution rights, and shall be free of any restriction whatsoever. RGI and JTRIL shall hereinafter jointly
be referred to as the "Subscriber". All shares issued to Subscriber pursuant to this Agreement shall hereinafter be referred to as "Shares".

 

	
3.2  
	
Note. OSI shall issue and deliver to RGI a promissory, non-recourse demand note ("Note") in the amount of $150,000. Principal on the note shall payable in 24 (twenty four) equal monthly installments of $6,250. RGI shall have the right to accelerate any or all of the unpaid principal due on the Note at any time. While any portion of the Note remains unpaid,
interest shall accrue on any outstanding principal balance at a rate of 6.5% per annum.

 

4.           TERM

This Agreement shall commence on the Effective Date, and will continue in full force and effect until the expiration of the last to expire of the Patents; provided, however, that

 

 

4

 

 

OSI's license to the RGI Technology will survive the expiration (but not the earlier termination) of this Agreement if this Agreement were otherwise in effect on the date of the last of the Patents to expire.

5.       REGULATORY COMPLIANCE

 

OSI shall at its own expense maintain compliance with all federal, state and local regulatory provisions as they may apply to the Product. These may include, but shall not be limited to:

 

	
5.1  
	
Submission for and obtainment of a new section 510(k) notification from the Food and Drug Administration covering the Product and all subsequent or alternative versions of the Product.

 

	
5.2  
	
Submission to the Food and Drug Administration of forms FDA 2891 and FDA 2892, respectively registering OSI as a Device Establishment and listing the Product as a Medical Device for OSI. RGI consents to these changes, and RGI consents to the use of its establishment registration number by OSI on an exclusive basis.

 

	
5.3  
	
Compliance with all general controls and special control provisions of the Federal Food, Drug and Cosmetic Act, including, without limitation provisions in the Code of Federal Regulations, Title 21, Parts 800 to 895, and compliance with current Good Manufacturing Practice (GMP), as set forth in the Quality System Regulation (QS) for Medical Devices: General
Regulation (21 CFR Part 820).

6.          CONDITIONS PRECEDENT

 

	
6.2  
	
Ross and OSI shall enter into an Employment Agreement to serve as Chairman & CEO of OSI.

 

	
6.3  
	
Ross shall execute Assignment Agreements in favor of OSI, in terms of which the Patents, the Oxysure Logo Trademark, Oxysure Name Trademark, and the Oxysure Tag Line Trademark shall be assigned to OSI.

 

7.           RESTRICTIONS ON TRANSFER

 

	
7.1  
	
Subscriber Representations. In connection with the issuance of Shares under this Agreement, the Subscriber hereby represents and warrants to the Company as follows:

 

	
7.2  
	
The Subscriber is acquiring and will hold the Shares for investment for his or her account only and not with a view to, or for resale in connection with, any "distribution" thereof within the meaning of the Securities Act.

 

5

 

 

	
  7.2   
	
 The Subscriber understands that the Shares have not been registered under the Securities Act by reason of a specific exemption therefrom and that the Shares must be held indefinitely, unless they are subsequently registered under the Securities Act or the Subscriber obtains an opinion of counsel, in form and substance satisfactory to the Company and its counsel, that such registration is not required. The Subscriber
further acknowledges and understands that the Company is under no obligation to register the Shares.

 

	
7.3  
	
The Subscriber is aware of the adoption of Rule 144 by the Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions, including (without limitation) tire availability of certain current public information about the
issuer, the resale occurring only after the holding period required by Rule 144 has been satisfied, the sale occurring through an unsolicited "broker's transaction," and the amount of securities being sold during any three-month period not exceeding specified limitations. The Subscriber acknowledges and understands that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company has no plans to satisfy these conditions in the foreseeable future.

 

	
7.4  
	
The Subscriber will not sell, transfer or otherwise dispose of the Shares in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder, including Rule 144 under the Securities Act. The Subscriber agrees that he or she will not dispose of the Shares unless and until he or she has complied with all requirements
of this Agreement applicable to the disposition of Shares and he or she has provided the Company with written assurances, in substance and form satisfactory to the Company, that (A) the proposed disposition does not require registration of the Shares under tire Securities Act or all appropriate action necessary for compliance with the registration requirements of the Securities Act or with any exemption from registration available under the Securities Act (including Rule 144) has been taken and (B) the proposed
disposition will not result in the contravention of any transfer restrictions applicable to the Shares under tire Rules of the California Corporations Commissioner.

 

	
7.5  
	
The Subscriber has been furnished with, and has had access to, such information as he or she considers necessary or appropriate for deciding whether to invest in the Shares, and the Subscriber has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the issuance of the Shares.

 

	
7.6  
	
The Subscriber is aware that his or her investment in the Company is a speculative investment that has limited liquidity and is subject to the risk of complete loss. The Subscriber is able, without impairing his or her financial condition, to hold the Shares for an indefinite period and to suffer a complete loss of his or her investment in the Shares.

 

 

6

 

 

 

	
7.7   
	
Securities Law Restrictions. Regardless of whether the offering and sale of Sharesunder this Agreement have been registered under the Securities Act or have been registered or qualified under the securities laws of any state, the Company at its discretion
may impose restrictions upon the sale, pledge or other transfer of the Shares (including the placement of appropriate legends on stock certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order
to achieve compliance with the Securities Act, the securities laws of any state or any other law.

 

	
7.8   
	
Market Stand-Off. In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company's initial public offering, the Subscriber
shall not directly or indirectly sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the
foregoing transactions with respect to, any Shares without the prior written consent of the Company or its underwriters. Such restriction (the "Market Stand-Off3) shall be in effect for such period of time
following the date of the final prospectus for the offering as may be requested by the Company or such underwriters. In no event, however, shall such period exceed 180 days. The Market Stand-Off shall in any event terminate two years after the date of the Company's initial public offering.
In the event of the declaration of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company's outstanding securities without receipt of consideration, any new, substituted or additional
securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. In order to enforce the Market Stand Off, the Company
may impose stop-transfer instructions with respect to the Shares until the end of the applicable stand-off period. The Company's underwriters shall be beneficiaries of the agreement set forth in this Subsection 7.8. This Subsection 7.8 shall not apply to Shares registered in
the public offering under the Securities Act, and the Subscriber shall be subject to this Subsection 7.8 only if the directors and officers of the Company are subject to similar arrangements.

 

	
  7.9   
	
Rights of the Company. The Company shall not be required to (i) transfer on its books any Shares that have been sold or transferred in contravention of this Agreement or (ii) treat as the owner of Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom Shares have been transferred in contravention of this Agreement.

8.      LEGENDS

 

Legends. All certificates evidencing the Shares shall bear the following legends:

 

 

7

 

 

"THE SHARES REPRESENTED HEREBY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR JN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER OF THE SHARES (OR THE PREDECESSOR IN INTEREST TO THE SHARES). THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH
A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE."

 

"THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED."

 

If required by the authorities of any state in connection with the issuance of the Shares, the legend or legends required by such state authorities shall also be endorsed on all such certificates.

 

9.      MISCELLANEOUS PROVISIONS

 

	
  9.1  
	
Governing Law. This Agreement, and any dispute arising from the performance or breach hereof, will be governed by and construed and enforced in accordance with the laws of the State of Texas, without reference to conflicts of laws principles. The prevailing party in any legal action to enforce or interpret this Agreement shall be entitled to reasonable costs and attorneys' fees and expenses in connection therewith.

 

	
9.3  
	
Assignment. Neither party may assign this Agreement without the prior written consent of the other party, except that either party may assign this Agreement without such consent to an entity that acquires all or substantially all of the business or assets of such party pertaining to the subject matter hereof, whether by merger, reorganization, acquisition,
sale or otherwise. Any other attempted assignment of this Agreement will be void. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties and their successors, heirs and assigns.

 

	
9.4  
	
Notices. All notices, requests and other communications hereunder will be in writing and will be personally delivered or sent by telecopy or other electronic facsimile transmission or by registered or certified mail, return receipt requested, postage prepaid, or overnight courier, in each case to the respective address appearing below each party's signature,
or such other address as may be specified in writing to the other party hereto.

 

	
9.5  
	
Partial Invalidity. If any provision of this Agreement is held to be invalid by a court of competent jurisdiction, then the remaining provisions will remain, nevertheless, in full force and effect. The parties agree to renegotiate in good faith any provision held invalid and to
be bound by the mutually agreed substitute provision in order to give the most approximate effect originally intended by the parties.

 

  

8

  

 

 

	
9.6  
	
Severability. In the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement will remain in full force and effect without said provision. In such event, the parties will in good faith negotiate a substitute clause for any provision declared invalid or
unenforceable, which will most nearly approximate the intent of the parties in entering this Agreement.

 

	
9.7  
	
Waiver. It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth will be deemed a waiver as to any subsequent and/or similar breach or default.

 

	
9.8  
	
Complete Agreement. This Agreement (together with the applicable provisions of the Merger Agreement) constitutes the entire agreement, both written and oral, between the parties with respect to the subject matter hereof, and mat all prior agreements respecting the subject matter hereof, either written or oral, expressed or implied, are merged and canceled,
and are null and void and of no effect. No amendment or change hereof or addition hereto will be effective or binding on either of the parties hereto unless reduced to writing and duly executed on behalf of both parties hereto.

 

	
9.9  
	
Headings. The captions to the Sections hereof are not a part of this Agreement, but are included merely for convenience of reference only and will not affect its meaning or interpretation.

 

	
9.10  
	
Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original and which together will constitute one instrument.

 

  

9

  

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement on the date first above written.

 

 

STATE OF TEXAS  

 

COUNTY OF COLLIN

 

BEFORE ME, the undersigned, on this day personally appeared Julian Ross, known to me to be the person executing the foregoing document, and stated that he executed the same for the pruposes and considerations therein expressed. 

 

IN WITNEDD WHEREOF, I have set my hand and official seal, on this 26th day of April, 2004

 

 

____________________________________

Notary Public, State of Texas

 

 

 

 

 

10Unassociated Document

AGREEMENT

 

This Agreement ("Agreement") is made and entered into on June 22, 2009 by and between OxySure Systems, Inc., a Delaware Corporation ("OxySure") and IR Services, Inc., a Nevada Corporation ("IR Services") (jointly, the "Parties"). This Agreement supersedes all prior agreements between the Parties and among the Parties and Donson Brooks.

 

WITNESSETH

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties to this Agreement, said parties agree as follows:

 

(a)           OxySure agrees to engage the services of IR Services, Inc. to provide or engage

appropriate professionals to provide the following:

 

	•    	
Prepare and submit an S-1 filing to the SEC; OR provide a fully reporting Form 10 company, fully compliant with SEC (the "Form 10 Company") for OxySure to merge with.

	•    	Prepare and submit an 8K filing to the SEC, if applicable
	•    	Prepare and submit responses to SEC comment letters
	•    	Prepare and submit a 15c211 filing to a Brokerage firm for a filing to FESTRA
	•    	Prepare and submit responses to FINRA comment letters
	•    	
Retain the services of an acceptable Market Maker, Broker Dealer, and Escrow Agent

	•    	
Provide such other services and activities as necessary to obtain a ticker symbol and become traded on the Over-the-Counter Bulletin Board (OTCBB)

 

	
  
	
(b)
	
OxySure will require updated audited financial statements for SEC compliance. OxySure agrees to cover up to $2,000 of the cost of obtaining such updated audited financial statements for SEC compliance. If the cost of obtaining the updated audited financial statements
exceeds $2,000 then IR-Services will pay the difference between the actual cost and $2,000., only upon engaging the CPA services of the Blackwing Group, LLC,a PCOAB member.

 

	
  
	
(c)
	
If OxySure becomes traded on OTCBB, IR Services or an acceptable assignee will provide OxySure with Investor Relations Services, which shall include, without limitation, press releases, investor awareness campaigns (online and mail), and blog and message
board monitoring. These Investor Relations Services will be provided for period of 9 months commencing on the date that OxySure first becomes publicly traded.

 

	 	(e) 	OxySure Systems, Inc., agrees to pay IR Services, Inc. $50,000 in cash and to sell IR Services, Inc. 968,419 penny warrants (the "Warrants"). The form of the Warrant is annexed hereto as Exhibit A.

 

	
(f)      
	
IR Services will secure a Market Maker at its sole expense, which Market Maker shall be reasonably acceptable to OxySure.

 

	
(g)      
	
OxySure will provide all the information exhibits and financial statements required by IR Services, Inc., in a timely manner no later than 60 days subsequent to the Effective Date of the Agreement.

 

 

 

 

 

	
1.   
	
Representations and Warranties. The parties to this Agreement, and their agents represent and warrant they are entering into this Agreement and the performance by them, and their agents hereunder will
not conflict with, violate or constitute a breach of, or require any consent or approval under any agreement, license, arrangement or understanding, or any law, judgment, decree, order, rule or regulation to which they and their agents are a party or by which it is bound.

 

	 	
The signatories and parties to this agreement warrant that they are authorized to enter into this agreement and is binding upon the parties hereto. All entities which are parties to this agreement warrant that they are in good standing and current with their states or locations of domicile and that their entering into this agreement will
not violate or breach any other binding agreement of the parties.

 

	
2.  
	
Severability. If any provision of this Agreement is invalid and unenforceable in any jurisdiction, then to the fullest extent permitted by law: (1) the other provisions hereof shall remain in full force and effect in such jurisdiction; and (2) the invalidity or unenforceability of any provision
hereof in any jurisdiction shall not affect the validity or unenforceability of such provision in any other jurisdiction.

 

	
3.  
	
Entire Agreement. This Agreement contains the entire understanding and agreement between the parties with respect to the subject matter hereof and cannot be amended, modified or supplemented in any respect except by a subsequent written agreement entered into by the parties.

 

	
4.  
	
Successors. This Agreement may not be assigned. Subject to the foregoing, in every respect, this Agreement shall inure to the benefit of and be binding upon the parties and their successors.

 

	
5.  
	
Effect of Waiver. The waiver by either party of a breach of any provision of this Agreement shall not operate, to as or be construed as a waiver of any subsequent breach.

 

	
6.  
	
Notices. Any notice, request, demand or other communication in connection with this Agreement shall be (i) in writing, (ii) delivered by personal delivery, or sent by commercial delivery service or registered or certified mail, return receipt requested or sent by facsimile, (iii) deemed to
have been given on the date of personal delivery or the date set forth in the records of the delivery service or on the return receipt or, in the case of a facsimile, upon receipt thereof and (iv) addressed as follows:

 

	IR Services, Inc.    	OxySure Systems, Inc.
	8586 Warren Pkwy  	10880 John W. Elliot Drive
	Suite 827  	Suite 600
	Frisco, Texas 75034     	Frisco, Texas 75034
	(469) 499-4495   	(972) 294-6501
	 	 

 

or to any such other or additional persons and addresses as the parties may from time to time designate in writing delivered in accordance with this Section.

 

	
7.  
	
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

	
8.  
	
Applicable Law. This Agreement shall be governed by, and construed in accordance with the laws of the State of Texas. In the event any action be instituted by a party to enforce any of the terms and provisions contained
herein, the prevailing party in such action shall entitled to such reasonable attorneys' fees, costs and expenses as may be fixed by the Court.

  

  

  

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as the day and year first stated above.

 

 

OxySure Systems, Inc. 

 

 

 

 

 

 

 

EXHIBIT A 

 

STOCK PURCHASE WARRANT

 

NEITHER THIS WARRANT NOR ANY SECURITIES ON EXERCISE HEREOF HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF REGISTRATION UNDER SUCH ACT AND APPLICABLE LAWS, OR THE AVAILABILITY OF
AN EXEMPTION FROM SUCH REGISTRATION, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT LEGALLY REQUIRED.

 

STOCK PURCHASE WARRANT

 

 

This Stock Purchase Warrant (this "Warrant'''), dated_____________ , is issued to__________________ (the "Holder"), by OxySure Systems,
Inc., a Delaware corporation (the "Company").

 

1.           Purchase of Shares. Subject to the terms and conditions hereinafter set forth, the Holder is entitled, upon surrender of this
Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof in writing), to purchase from the Company_______fully paid and non-assessable shares of Common Stock, par value $0.0004_________per share (the "Common Stock'), of the
Company (as adjusted pursuant to Section 7 hereof, the "Shares") for the purchase price specified in Section 2 below.

 

2.           Purchase Price. The purchase price for the Shares is $ ________per share. Such price

shall be subject to adjustment pursuant to Section 7 hereof (such price, as adjusted from time to time, is herein referred to as the "WarrantPrice").

 

3.           Exercise Period. This Warrant is exercisable in whole or in part at any time from the date

 

hereof through____________________                                .

 

4.         Transfer of Warrant. Transfer of this Warrant to a third party shall be effected by execution and delivery of the Notice of Assignment
attached hereto as Exhibit AA and surrender of this Warrant for registration of transfer of this Warrant at the primary executive office of the Company, together with funds sufficient to pay any applicable transfer tax, Upon receipt of the duly executed Notice of
Assignment and the necessary transfer tax funds, if any, the Company, at its expense, shall execute and deliver, in the name of the designated transferee or transferees, one or more new Warrants representing the right to purchase a like aggregate number of shares of Common Stock.

 

5.          Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section
3 above, the Holder may exercise, in whole or in part, the purchase rightsevidenced hereby. Such exercise shall be effected by:

 

(a) surrender of this Warrant, together with a duly executed copy of the form of Exercise Notice attached hereto, to the Secretary of the Company at its principal offices, and the payment to the Company of an amount
equal to the aggregate purchase price for the number of Shares being purchased, which shall be a whole number of shares; or

 

(b) if the Common Stock is publicly traded as of such date, the instruction to retain that whole number of Shares having a value equal to the aggregate exercise price of the Shares as to which this Warrant is being
exercised and to issue to the Holder the remainder of such Shares computed using the following formula:

 

 

 

 

 

X-      Y(A-B)/A

 

Where:

 

X =     the number of shares of Common Stock to be issued to the Holder. 

 

Y=      the number of shares of Common Stock as to which this Warrant is being exercised. 

 

A -     the fair market value of one share of Common Stock. 

 

B =      the Warrant Price. As used herein, the "fair market value of one share of Common Stock" shall mean:

 

(1) Except in the circumstances described in clause (2) hereof, the price per share of the Common Stock determined in good faith by the Board of Directors of the Company; or

 

(2) If such exercise is in conjunction with a merger, acquisition or other consolidation pursuant to which the Company is not the surviving entity, the value received by the holders of the Common Stock pursuant to such transaction for
each share.

 

6.           Certificates for Shares; Partial Exercise of Warrants.

 

(a) Upon the exercise of the purchase rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the
delivery of the Exercise Notice.

 

(b) If this Warrant is surrendered for partial exercise, the Company shall execute and deliver to the Holder of the Warrant, without charge to the Holder, a new Warrant exercisable for an aggregate number of shares
of Common Stock equal to the unexercised portion of the surrendered Warrant.

 

7. Reservation of Shares. The Company covenants that it will at all times keep available such number of authorized shares of its Common Stock, free
from all preemptive rights with respect thereto, which will be sufficient to permit the exercise of this Warrant for the full number of Shares specified herein. The Company further covenants that such Shares, when issued pursuant to the exercise of this Warrant, will be duly and validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issuance thereof.

 

8. Adjustment of Warrant Price and Number of Shares. The number and kind of securities purchasable upon exercise of this Warrant and the Warrant Price
shall be subject to adjustment from time to time as follows:

 

(a)       Stock Dividends, Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of this Warrant subdivide its Common Stock, by stock split or otheiwise, combine its Common Stock or
issue additional shares of its Common Stock as a dividend with respect to any shares of its Common Stock, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend and proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted)
shall remain the same. Any adjustment under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes effective or as of the record date of such dividend, or, in the event that no record date is fixed, upon the making of such dividend.

 

 

 

 

 

(b)       Reclassification, Reorganization, Merger, Sale or Consolidation, In the event of any reclassification, capital reorganization or other change in the Common Stock of the Company (other than as a result of a subdivision, combination
or stock dividend provided for in Section 7(a) above) or in the event of a consolidation or merger of the Company with or into, or the sale of all or substantially all of the properties and assets of the Company, to any person, and in connection therewith consideration is payable to holders of Common
Stock in cash, securities or other property, then as a condition of such reclassification, reorganization or change, consolidation, merger or sale, lawful provision shall be made, and duly executed documents evidencing the same shall be delivered to the Holder, so that the Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant immediately prior to such event, the kind and amount of cash, securities or
other property receivable in connection with such reclassification, reorganization or change, consolidation, merger or sale, by a holder of the same number of shares of Common Stock as were exercisable by the Holder immediately prior to such reclassification, reorganization or change, consolidation, merger or sale. In any such case, appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any cash, securities
or property deliverable upon exercise hereof. Notwithstanding the foregoing, (i) if the Company merges or consolidates with, or sells all or substantially all of its property and assets to, any other person, and consideration is payable to holders of Common Stock in exchange for their Common Stock in connection with such merger, consolidation or sale which consists solely of cash, or (ii) in the event of the dissolution, liquidation or winding up of the Company, then the Holder shall be entitled to receive distributions
on the date of such event on an equal basis with holders of Common Stock as if this Warrant had been exercised immediately prior to such event, less the Warrant Price. Upon receipt of such payment, if any, the rights of the Holder shall terminate and cease, and this Warrant shall expire. In case of any such merger, consolidation or sale of assets, the surviving or acquiring person and, in the event of any dissolution, liquidation or winding up of the Company, the Company shall promptly, after receipt of this
surrendered Warrant, make payment by delivering a check in such amount as is appropriate (or, in the case of consideration other than cash, such other consideration as is appropriate) to such person as it may be directed in writing by the Holder surrendering this Warrant.

 

9. Pre-Exercise Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a shareholder with respect to the Shares,
including without limitation, the right to vote such Shares, receive preemptive rights or be notified of shareholder meetings, and the Holder shall not be entitled to any notice or other communication concerning the business or affairs of the Company.

 

10. Certification of Investment Purpose. Unless a current registration statement under the Securities Act of 1933, as amended, shall be in effect with
respect to the securities to be issued upon exercise of this Warrant, the Holder hereof, by accepting this Warrant, covenants and agrees that, at the time of exercise hereof, the Holder will deliver to the Company a written certification that the securities acquired by the Holder are acquired for investments purposes only and that such securities are not acquired with a view to, or for sale in connection with, any distribution thereof

 

11. Successors and Assigns. The terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the Holder and their respective
successors and assigns.

 

12. Governing Law. This Warrant shall be governed by the laws of the State of Texas, excluding the conflicts of laws provisions thereof.

 

IN WITNESS WHEREOF, the undersigned hereby agrees to the terms hereof effective as of

 

 

	 	 	COMPANY: OXYSURE SYSTEMS, INC.	 
	
 
	 	
By: 
	 
	 	 	Name: 	 
	 	 	Title: 	 

 

 

 

 

 

 

 Dated:__________,_______________

 

The undersigned hereby irrevocably elects to exercise the Stock Purchase Warrant, dated,  ____________________ , issued by________________________, a        

 

corporation (the "Company"), to the undersigned to the extent of purchasing ______________________ shares of Common Stock

 

and hereby makes payment of $______________________in payment of the aggregate Warrant Price of such Shares.

 

 

	 	 	
COMPANY:
	 
	 	 	
 

 
	 
	 	 	
By:
	 
	 	 	
 
	 
	 	 	
Name:
	 
	 	 	
 
	 
	 	 	Title:	 

 

 

 

 

 

 

 

Exhibit A 

ASSIGNMENT FORM

 

(To he executed only upon the assignment of the witMn Warrant)

 

FOR VALUE RECEIVED, the undersigned registered Holder of the within Warrant hereby sells, assigns and

 

transfers unto______________________ , whose address is

 

_______________________all of the rights of the undersigned under the within Warrant, with respect to shares of Common Stock (as defined within the Warrant) of OxySure Systems, Inc., and, if such shares of Common Stock shall not include all the shares of
Common Stock issuable as provided in the within Warrant, that a new Warrant of like tenor for the number of shares of Common Stock not being transferred hereunder be issued in the name of and delivered to the undersigned, and does hereby irrevocably constitute and appoint___________attorney to register such transfer on the books ofOxySure Systems,
Inc. maintained for that purpose, with full power of substitution in the premises.

Dated:_____________________                            

 

 

Signature Guaranteed

 

By:_________________________________                                                              

(Signature of Registered Holder)

 

Title:____________________________                                                       

 

NOTICE:                      The signature to this Notice of Assignment must correspond with the
name upon the face of the within Warrant in every particular, without alteration or enlargement or any change whatever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]